Literature DB >> 26181247

Progress in Understanding What Is Being Statin(ed) in Prostate Cancer.

Jorge D Ramos1, Evan Y Yu1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26181247      PMCID: PMC5344994          DOI: 10.1001/jamaoncol.2015.0833

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN: 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  15 in total

1.  The risk of cancer in users of statins.

Authors:  Matthijs R Graaf; Annette B Beiderbeck; Antoine C G Egberts; Dick J Richel; Henk-Jan Guchelaar
Journal:  J Clin Oncol       Date:  2004-06-15       Impact factor: 44.544

2.  SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer.

Authors:  Ming Yang; Wanling Xie; Elahe Mostaghel; Mari Nakabayashi; Lillian Werner; Tong Sun; Mark Pomerantz; Matthew Freedman; Robert Ross; Meredith Regan; Nima Sharifi; William Douglas Figg; Steven Balk; Myles Brown; Mary-Ellen Taplin; William K Oh; Gwo-Shu Mary Lee; Philip W Kantoff
Journal:  J Clin Oncol       Date:  2011-05-23       Impact factor: 44.544

3.  Statins and the risk of colorectal cancer.

Authors:  Jenny N Poynter; Stephen B Gruber; Peter D R Higgins; Ronit Almog; Joseph D Bonner; Hedy S Rennert; Marcelo Low; Joel K Greenson; Gad Rennert
Journal:  N Engl J Med       Date:  2005-05-26       Impact factor: 91.245

4.  Statins reduce the risk of lung cancer in humans: a large case-control study of US veterans.

Authors:  Vikas Khurana; Hanmanth R Bejjanki; Gloria Caldito; Michael W Owens
Journal:  Chest       Date:  2007-05       Impact factor: 9.410

5.  The androgen axis in recurrent prostate cancer.

Authors:  James L Mohler; Christopher W Gregory; O Harris Ford; Desok Kim; Catharina M Weaver; Peter Petrusz; Elizabeth M Wilson; Frank S French
Journal:  Clin Cancer Res       Date:  2004-01-15       Impact factor: 12.531

6.  Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer.

Authors:  Elahe A Mostaghel; Stephanie T Page; Daniel W Lin; Ladan Fazli; Ilsa M Coleman; Lawrence D True; Beatrice Knudsen; David L Hess; Colleen C Nelson; Alvin M Matsumoto; William J Bremner; Martin E Gleave; Peter S Nelson
Journal:  Cancer Res       Date:  2007-05-15       Impact factor: 12.701

7.  Impact of circulating cholesterol levels on growth and intratumoral androgen concentration of prostate tumors.

Authors:  Elahe A Mostaghel; Keith R Solomon; Kristine Pelton; Michael R Freeman; R Bruce Montgomery
Journal:  PLoS One       Date:  2012-01-18       Impact factor: 3.240

8.  Statin use and risk of prostate cancer: a meta-analysis of observational studies.

Authors:  Dipika Bansal; Krishna Undela; Sanjay D'Cruz; Fabrizio Schifano
Journal:  PLoS One       Date:  2012-10-01       Impact factor: 3.240

9.  Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy.

Authors:  Jonathan R Emberson; Patricia M Kearney; Lisa Blackwell; Connie Newman; Christina Reith; Neeraj Bhala; Lisa Holland; Richard Peto; Anthony Keech; Rory Collins; John Simes; Colin Baigent
Journal:  PLoS One       Date:  2012-01-19       Impact factor: 3.240

Review 10.  Beyond T and DHT - novel steroid derivatives capable of wild type androgen receptor activation.

Authors:  Elahe A Mostaghel
Journal:  Int J Biol Sci       Date:  2014-06-03       Impact factor: 6.580

View more
  3 in total

Review 1.  Targeting intratumoral androgens: statins and beyond.

Authors:  Michael T Schweizer; Evan Y Yu
Journal:  Ther Adv Med Oncol       Date:  2016-05-11       Impact factor: 8.168

2.  Influence of serum cholesterol level and statin treatment on prostate cancer aggressiveness.

Authors:  Thomas J Schnoeller; Florian Jentzmik; Andres J Schrader; Julie Steinestel
Journal:  Oncotarget       Date:  2017-07-18

Review 3.  Persistent androgen receptor addiction in castration-resistant prostate cancer.

Authors:  Michael T Schweizer; Evan Y Yu
Journal:  J Hematol Oncol       Date:  2015-11-13       Impact factor: 17.388

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.